Effects of the sodium‐glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptanKen Ohara, Daisuke Nagata, Takahiro Masuda et al.|Nephrology|2018Cited by 82
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney diseaseKen Ohara, Daisuke Nagata, Saki Nakagawa et al.|Diabetology & Metabolic Syndrome|2020Cited by 66
Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid RetentionTakahiro Masuda, Daisuke Nagata, Takuya Murakami et al.|Internal Medicine|2016Cited by 26
Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patientsTakahiro Masuda, Daisuke Nagata, Ken Ohara et al.|International Urology and Nephrology|2019Cited by 23
Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of FallotKen Ohara, Daisuke Nagata, Tetsu Akimoto et al.|Clinical Medicine Insights Case Reports|2015Cited by 9